Browsing by author "Burnett, Stephanie"
Now showing items 1-3 of 3
-
BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004).
Kelly, JD; Tan, WS; Porta, N; Mostafid, H; Huddart, R; et al. (ELSEVIER SCIENCE BV, 2019-04-01)BACKGROUND: Non-muscle-invasive bladder cancer (NMIBC) has a significant risk of recurrence despite adjuvant intravesical therapy. OBJECTIVE: To determine whether celecoxib, a cyclo-oxygenase 2 inhibitor, reduces the risk ... -
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Brand, DH; Tree, AC; Ostler, P; van der Voet, H; Loblaw, A; et al. (ELSEVIER SCIENCE INC, 2019-09-17)BACKGROUND: Localised prostate cancer is commonly treated with external-beam radiotherapy. Moderate hypofractionation has been shown to be non-inferior to conventional fractionation. Ultra-hypofractionated stereotactic ... -
VinCaP: a phase II trial of vinflunine in locally advanced and metastatic squamous carcinoma of the penis.
Nicholson, S; Tovey, H; Elliott, T; Burnett, SM; Cruickshank, C; et al. (SPRINGERNATURE, 2022-01-01)BACKGROUND: We investigated the first-line activity of vinflunine in patients with penis cancer. Cisplatin-based combinations are commonly used, but survival is not prolonged; many patients are unfit for such treatment or ...